The Anti-Infectives Market Outlook to 2013
The market for anti-infectives related disorders is set to become increasingly challenging as growing numbers of infectious pathogens become resistant to existing therapies. The resultant shift in R&D strategies has become a driving force behind market transformation, with many manufacturers now focused on developing drugs to counter resistance. Developmental focus has also shifted away from the anti-fungal and anti-bacterial markets due to increasing levels of genericization and comparatively shorter treatment regimens compared to other indications. By contrast, the anti-viral market contains large patient populations with chronic infections that require lifelong treatment, in addition to existing therapies that fail to provide adequate treatment.
‘The Anti-Infectives Market Outlook to 2013’ is a report published by Business Insights that provides comprehensive coverage of the major markets in the global anti-infectives area, incorporating a detailed epidemiological analysis of the four major indications and key factors impacting their prevalence. This report profiles the factors and underlying trends that are driving market transformation and identifies the most promising areas of potential growth. Current leading brands of treatment within each indication are assessed and ten of the market’s leading players are profiled. Sales forecasts for currently marketed and key pipeline products over the 2008-13 period are also provided.
Discover the key trends and growth drivers of the anti-infectives market, assess the competitive dynamics of leading companies and evaluate the future prospects of major products with this report...
Assess leading developmental products within each indication, identify potential growth opportunities and assess leading companies within the anti-infectives market with this report...

Some key findings from this report...
• The global anti-infectives market is forecast to expand at a CAGR of 5.7% between 2008-13. Sales of anti-virals and vaccines are forecast to grow by 7.5% and 9.0% respectively, comfortably outperforming overall market growth during this period.
• The ten leading companies in the anti-infectives market accounted for 53.8% ($37.3bn) of total revenues in 2007. The competitive landscape remains highly fragmented, with market leaders Merck and GSK controlling a combined market share of only 21.4%.
• Anti-bacterials accrued sales of $36.3bn in 2007, accounting for 52.3% of total market revenues. Major growth drivers in this drug class are the cepahalosporins and fluroquinolones, which amassed combined sales of $16.0bn, 45% of total anti-bacterial revenues.
• Anti-fungals were the only drug class to experience a decline in sales over the 2006–2007 period, with a reduction of 2.7%. This is largely attributable to fewer new product launches and toxicity concerns relating to major marketed drugs.
• Market leader GSK is forecast to report a 2% decline in revenue share between 2008-13 due to upcoming patent expirations and a weak developmental pipeline for HIV treatments.

Top reasons to order your copy today
• Assess the epidemiology and forecast prevalence of anti-fungal, anti-bacterial, anti-viral and vaccine markets across major countries including the UK, Japan, France, Germany, Italy, Spain and the US.
• Measure the market performance and strategic positioning of major anti-infectives developers with this report’s evaluation of the franchises and market shares of Abbot, BMS, Gilead Sciences, GSK, J&J, Merck, Novartis, Pfizer, Sanofi-Aventis and Wyeth.
• Identify the market dynamics for the global anti-infectives area and understand the impact of recent key events by assessing major market trends, growth drivers and the latest issues affecting R&D.
• Predict revenues for major currently marketed and pipeline anti-infective products over 2008-13, with this report’s sales forecasts across major indications, treatment classes and company portfolios.
• Discover the strategies that offer the greatest success potential for anti-infectives developers in the future and understand the challenges currently facing companies within this therapeutic area.

Key issues examined in this report...
• Shifting R&D focus for vaccines. The arrival of vaccines that can treat HPV and Herpes Zoster will act as a catalyst for transition within the R&D pipeline. Potential further launches of groundbreaking novel vaccines will help to maintain robust market growth.
• Opportunities in anti-virals. The anti-virals market bears significant future commercial opportunity, with growth in the sector being fuelled by the constant threat of drug resistance, unmet medical need, large patient markets and sub-optimal standards of care.
• Hepatitis C therapies fuel growth. New drug classes in development have the potential to offer significant improvements in efficacy, convenience and tolerability over existing treatment regimens.
• Emerging anti-bacterial trends. Growing concerns over infections caused by gram-negative organisms such as acinetobacters has driven sales of currently marketed products and also catalyzed a shift in R&D focus amongst anti-bacterial developers.

Your questions answered...
• What will be the major growth indications and drivers within the anti-infectives market between 2008-13?
• What are the major current trends within anti-fungals, anti-bacterials, anti-virals and vaccines across the seven major markets?
• How have recent launches from companies such as GSK, Merck, and Pfizer performed?
• What is the forecast commercial potential of the most promising compounds in clinical development?
• What is the forecast market size and growth rate of major anti-infective indications?
• How significant is the threat of generics to the global market?
• Which major pipeline developments will shape future strategies?
• How will the competitive landscape of the global anti-infectives market change over 2008-13?

Publication: 39661
Library Code: rbhc0207
Type: Report
Format: PDF
Pages: 212